Practical guide
Inflation Reduction Act Drug Price Negotiations: What It Means
Medicare is finally negotiating lower costs for 2026. Learn how these new drug prices affect your pharmacy bills and help you save money on prescriptions.
If you’ve ever felt the shock of a high pharmacy bill for a maintenance medication, you’re not alone. For millions of Americans on Medicare, the cost of essential prescriptions has been a significant financial burden. As of 2026, however, a major change is taking full effect. The Inflation Reduction Act (IRA) has empowered Medicare to negotiate prescription drug prices directly with manufacturers for the first time, and the results of those first negotiations are finally reaching your pharmacy counter.
This isn’t just a minor policy tweak; it’s a fundamental shift designed to lower out-of-pocket costs for seniors. Understanding how these new rules work, which drugs are affected, and what it means for your budget is crucial. This guide breaks down the complex law into what matters most: the impact on your wallet.
How the Inflation Reduction Act Lowers Your Prescription Drug Costs
For years, Medicare was legally prohibited from negotiating drug prices, unlike the Department of Veterans Affairs or private insurance companies. The Inflation Reduction Act, signed into law in 2022, changed that. Its primary goal is to make prescription drugs more affordable for the 65 million Americans enrolled in Medicare. The law tackles this through several key provisions that work together to reduce your spending.
First and foremost is the new Medicare Drug Price Negotiation Program. Under this program, the Centers for Medicare & Medicaid Services (CMS) can now negotiate directly with pharmaceutical companies to establish a “Maximum Fair Price” for certain high-expenditure drugs that lack generic or biosimilar competition. This directly addresses the core issue of high list prices for brand-name medications that many seniors rely on.
Beyond direct negotiations, the law introduces other critical financial protections. It established a firm annual cap on out-of-pocket prescription drug costs for people with Medicare Part D, a change that took effect in 2025 and continues in 2026. It also requires drug companies to pay rebates to Medicare if they raise their prices faster than the rate of inflation, a measure aimed at curbing steep price hikes on existing drugs. Combined, these elements create a powerful new framework for controlling your prescription expenses.
The First 10 Drugs Selected for Price Negotiation in 2026
The negotiation process is being rolled out in phases, starting with a small but impactful list of medications. In 2023, CMS identified the first 10 drugs covered under Medicare Part D for the initial round of price negotiations. These drugs were selected based on their high total spending within the Medicare program and their long-standing presence on the market without competition. The newly negotiated prices for these specific drugs become effective on January 1, 2026.
The initial list includes widely used medications for treating some of the most common conditions among older adults, including heart disease, blood clots, diabetes, and autoimmune disorders. If you take one of these medications, you are among the first group of beneficiaries who will see the direct financial benefit of these negotiations.
The 10 drugs included in this first round are:
- Eliquis: Prevents blood clots and stroke.
- Jardiance: Treats diabetes and heart failure.
- Xarelto: Prevents blood clots and stroke.
- Januvia: Treats diabetes.
- Farxiga: Treats diabetes, heart failure, and chronic kidney disease.
- Entresto: Treats heart failure.
- Enbrel: Treats rheumatoid arthritis and other autoimmune conditions.
- Imbruvica: Treats blood cancers.
- Stelara: Treats Crohn’s disease, psoriasis, and psoriatic arthritis.
- Fiasp; Novolog (Insulin Aspart): Rapid-acting insulin for diabetes.
The inclusion of blockbuster drugs like Eliquis and Jardiance signals a significant potential for savings, as these medications have long been major drivers of out-of-pocket spending for Medicare beneficiaries.
| Drug Name | Common Use | What the 2026 Negotiation Means for You |
|---|---|---|
| Eliquis | Blood Clot & Stroke Prevention | Potential for significantly lower monthly copays or coinsurance if you are on Medicare Part D. |
| Jardiance | Diabetes & Heart Failure | Your cost-sharing for this popular diabetes drug will be based on the new, lower Maximum Fair Price. |
| Xarelto | Blood Clot & Stroke Prevention | Similar to Eliquis, expect reduced out-of-pocket costs at the pharmacy starting in 2026. |
| Entresto | Heart Failure | This critical heart medication will become more affordable, easing the financial burden for long-term treatment. |
| Enbrel | Rheumatoid Arthritis | As a costly specialty biologic, the negotiated price could lead to substantial savings for patients. |
When You’ll See Savings and How Prices Are Set
A key question for everyone on Medicare is: when do these changes actually hit my wallet? The timeline is specific. While the negotiations took place through 2024, the new, lower prices—the “Maximum Fair Price” (MFP)—officially go into effect on **January 1, 2026**. Starting on that date, your Medicare Part D plan will base your copay or coinsurance for these 10 drugs on the new, negotiated price, not the manufacturer’s old list price.
The process for determining these prices is methodical. According to the Centers for Medicare & Medicaid Services (CMS), the negotiation process involves a careful exchange of information between CMS and the drug’s manufacturer. CMS evaluates a range of evidence, including the drug’s clinical benefit, its effectiveness compared to other treatments, costs of research and development, and data on production and distribution costs. The goal is to arrive at a price that reflects the drug’s therapeutic value while being fair to taxpayers and affordable for patients.
This process will continue in the coming years. For 2027, CMS will negotiate prices for an additional 15 drugs, followed by another 15 for 2028, and 20 more drugs for each year after that. This means the list of medications with lower, negotiated prices will steadily grow, bringing relief to more and more people over time.
Key Medicare Drug Cost Changes for 2026
- $2,000 Annual Out-of-Pocket Cap: This is the absolute maximum you will pay for all your covered Part D prescription drugs for the year. This cap first took effect in 2025 and provides a critical safety net.
- $0 Cost in Catastrophic Phase: Once your out-of-pocket spending reaches the $2,000 cap, you will pay $0 for your covered drugs for the remainder of the year. The 5% coinsurance in the catastrophic coverage phase has been eliminated.
- $35 Monthly Insulin Cap: Your cost for a one-month supply of any Part D-covered insulin product is capped at $35.
- Prescription Drug Inflation Rebates: This provision discourages sharp price increases by requiring manufacturers to pay a rebate to Medicare if they raise a drug’s price faster than the rate of inflation.
- 10 Negotiated Drugs: The first set of high-cost drugs will have their prices lowered to the new Maximum Fair Price, effective January 1, 2026.
Frequently Asked Questions About the Inflation Reduction Act Drug Prices
Is there a cap on out-of-pocket drug costs under the new law?
Yes, and it’s one of the most significant consumer protections in the law. As of 2025, there is a $2,000 annual cap on what you have to pay out-of-pocket for your Medicare Part D prescription drugs. This means that once your total spending on deductibles and copayments reaches $2,000 in a year, you will owe nothing more for your covered prescriptions for the rest of that year. This eliminates the dreaded catastrophic coverage phase where you previously had to pay 5% of the cost with no upper limit.
How are the negotiated drug prices determined by CMS?
The Centers for Medicare & Medicaid Services (CMS) determines the “Maximum Fair Price” through a structured negotiation with the drug’s manufacturer. CMS reviews extensive data, including the drug’s clinical efficacy, how it compares to alternative treatments, its invention and manufacturing costs, and its existing market price. The final negotiated price aims to balance the drug’s value with affordability for the Medicare program and its beneficiaries.
Do these new prices apply if I have private insurance through my employer?
No, the Medicare Drug Price Negotiation Program applies specifically to medications covered under Medicare Part D and Part B. If you have commercial health insurance through an employer or the ACA Marketplace, these negotiated prices do not directly apply to your plan. However, the broader effects of drug price transparency and lower government spending could eventually influence the commercial market. If you are seeking coverage outside of an employer, our ACA Marketplace Enrollment Guide for 2026 Coverage can help you navigate your options.
What if my medication isn’t on the negotiation list?
If your drug is not one of the first 10, you may still benefit from the IRA’s other provisions, like the $2,000 out-of-pocket cap. More drugs will be added to the negotiation list in the coming years. In the meantime, there are many other ways to manage high costs. It’s wise to explore all your options by consulting a Prescription Drug Cost Savings: Complete Guide. You can also investigate whether using a discount card is a better deal by comparing GoodRx vs Insurance: Which Pays Less for Your Prescription, or see if you qualify for assistance directly from the drug maker through Manufacturer Coupons for Prescription Drugs.
The Inflation Reduction Act represents a landmark change in how the United States approaches prescription drug costs for its seniors. The combination of direct price negotiation, a hard out-of-pocket cap, and inflation penalties creates a multi-layered system of financial protection. As the new prices for the first 10 drugs roll out in 2026, millions of Americans will begin to feel tangible relief.
The best thing you can do now is stay informed. During the annual Medicare Open Enrollment period this fall, carefully review your Part D plan options. Pay close attention to how your plan will cover the medications you take, especially if one of them is on the negotiation list. You can use the official Plan Finder tool on the CMS website, Medicare.gov, to compare plans and find the one that offers the best coverage and lowest costs for your specific needs.